Should protective chemotherapy for colon cancer last 6 months or 3 months?

The duration and choice of protective—adjuvant—chemotherapy after colon cancer surgery have long been debated. A comprehensive study presented at ASCO 2017 showed that, for “low-risk” stage 3 colon cancer patients, 3 months of chemotherapy is sufficient and promises far fewer side effects. It also showed no efficacy difference between CAPOX and FOLFOX drug combinations in adjuvant colon cancer treatment.
Colon and rectal cancers, cancers of the large bowel, are the 3rd most common cancers in both women and men in our country and an important cause of cancer-related death. As with all cancers, in colon cancer early diagnosis saves lives. In fourth-stage, or metastatic , colon cancer, treatment aims to prolong life, while in earlier stages it aims to reduce recurrence and save lives.
Accounting for approximately %40 of newly diagnosed colon cancers, stage 3 colon cancer is treated primarily by surgically removing the cancerous area and neighboring lymph nodes. At this stage, cancer has invaded bowel layers and/or spread to lymph nodes. Stage 3 colon cancer is divided by recurrence risk into low-risk and high-risk groups. Naturally, recurrence risk differs between stage 3 disease confined within bowel layers and involving fewer lymph nodes and cancer extending through all layers into surrounding tissue with many involved nodes (low risk T1-3 N1; high risk T4 and/or N2).
After surgery for stage 2 colon cancer, recurrence probability is around %20-30; in stage 3 it is around %50-80. Postoperative chemotherapy is given to reduce this probability. For many years, in stage 3 colon cancer, standard protective treatment to reduce recurrence was a combination of the chemotherapy drugs Oxaliplatin and Fluorouracil for 6 months. Medication is given intravenously every 14 days for two days, over 6 months in 12 cycles. In recent years, development of an oral form of Fluorouracil has made the treatment easier, though still given for 6 months. The first regimen is called FOLFOX; the regimen containing the oral chemotherapy capecitabine is called CAPOX. Studies to date have found similar efficacy for both. However, the cumulative nervous system effect of Oxaliplatin, a fixed component of both regimens, neuropathy, is the most unpleasant treatment side effect. It impairs quality of life and occurs in nearly half of patients.
- You may be interested in: Diagnosis and treatment of chemotherapy-related neuropathy (nerve damage)
Study
ASCO 2017 reported one of the largest studies ever conducted in oncology. It included patients with stage 3 colon cancer, totaling 12,800.
The study results can be summarized as follows:
- When all enrolled patients, both low- and high-risk, were assessed, disease-free survival at year 3 among those receiving 3 months of protective chemotherapy was %74.6, compared with 6 months at %75.5 (a difference of only % 1).
- In stage 3 colon cancer, %60 are low-risk patients. Their results showed, at year 3, disease-free survival with 3 months of treatment of %83.1, compared with 6 months at %83.3.
- Comparing chemotherapy regimens according to 3-year disease-free survival showed FOLFOX and CAPOX to be equally effective.
- The difference in neuropathy, the nerve damage side effect, was substantial. With 6 months of treatment, rates were %45 for FOLFOX and %48 for CAPOX; with 3 months, %15 for FOLFOX and %17 for CAPOX.
Conclusion
These results directly concern approximately 12 thousand patients newly diagnosed each year in our country with stage 3 colon cancer. For approximately %60 of these patients, those at low risk of recurrence, 3 months of protective chemotherapy emerges as a new standard with the same efficacy as 6 months and far fewer side effects.
.
Further reading: What are CAPOX and FOLFOX?
Drug combinations in chemotherapy involve administering two or more cancer drugs simultaneously. This aims to damage cancer cells in multiple ways at once, helping destroy them faster and more effectively. CAPOX and FOLFOX are two drug combinations used in colon cancer chemotherapy. CAPOX is derived from Capecitabine (brand name Xeloda) and Oxaliplatin. FOLFOX is derived from Leucovorin (Folinic acid), Fluorouracil (5-FU) and Oxaliplatin.
Fluorouracil is administered intravenously. Capecitabine is the form of Fluorouracil that can be taken orally as a tablet. Both belong to the drug group called antimetabolites. Antimetabolites target particular phases of the cell cycle. Cancer cells exposed to them lose the ability to divide, and cancer progression can be stopped.
Oxaliplatin is a chemotherapy drug that disrupts DNA structure. It aims to damage cancer cells’ DNA and thereby kill them.
Sources
2017 ASCO Annual Meeting. Abstract No: LBA1
2. Markle B, May EJ, Majumdar AP.
Do nutraceutics play a role in the prevention and treatment of colorectal cancer?
Cancer Metastasis Rev. 2010;29:395–404.
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.